Business Standard

Letters: No takers for R&D

Private players should wake up to the fact that research activities are the key to global opportunities and growth

Related News

This refers to the Q&A with J G Kulkarni "R&D and innovation find little place in Indian industry" (October 8). India is way behind countries like China, South Korea and Mexico in the field of research and development (R&D). To start with, academics and professionals in our country hardly show any interest in R&D. The shortage of people with doctorate degrees only adds to this problem. As a result, most research centres in India are running without talented research scholars.

It is only the public sector that is involved in R&D activities in India. But we need private participation to enhance competition in the field. Private players should wake up to the fact that research activities are the key to global opportunities and growth. For example, Glenmark has emerged as one of the well-known, research-based pharmaceuticals in India and its revenue has risen to $2.6 billion. Finally, a good amount of money should be earmarked for R&D activities because limited resources often come in the way of growth of research centres.

P Senthil Saravana Durai Mumbai

Letters can be mailed, faxed or e-mailed to:
The Editor, Business Standard
Nehru House, 4 Bahadur Shah Zafar Marg
New Delhi 110 002
Fax: (011) 23720201
E-mail: letters@bsmail.in
All letters must have a postal address and telephone number

Read more on:   
|
|

Read More

Letters: A common investor's woes

This refers to the edit “Trial and error” (October 26). Rajat Gupta merely helped a friend with insider tips and asked nothing in return. He is now ...

Quick Links

Have Your Say




There have been 10 major exits at Infosys in the past one year. What do you think is wrong with the company?

There have been 10 major exits at Infosys in the past one year. What do you think is wrong with the company?

Financial X-Ray Rss icon

Maruti: First-time, rural buyers drive volumes
Malini Bhupta

Sees double-digit volume growth in FY15; strong product pipeline to support higher realisations

US launches and India recovery key for Cadila

Given rich valuations, upside for the stock capped for now

Back to Top